MedTrace Logo

Glycaemic Markers in Persons With Type 2 Diabetes on Peritoneal Dialysis

NCT04125160 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2020-09-29

No results posted yet for this study

Summary

The aim is to investigate the correlation between mean glucose measured by continuous glucose monitoring (CGM) and mean glucose estimated from glycated haemoglobin A1c (HbA1c) in persons with type 2 diabetes undergoing peritoneal dialysis compared with patients with type 2 diabetes and normal renal function. Furthermore, the aim is to compare CGM and HbA1c with glycated albumin and fructosamine.

Conditions

  • HbA1c
  • Peritoneal Diseases
  • Glycated Albumin
  • Fructosamine
  • Continuous Glucose Monitoring

Interventions

DEVICE

Continuous glucose monitoring

Continuous glucose monitoring over 16 days

DIAGNOSTIC_TEST

Glycaemic markers

Measurement of HbA1c, glycated albumin and fructosamine.

Sponsors & Collaborators

  • Steno Diabetes Center Copenhagen

    collaborator OTHER

  • Zealand University Hospital

    collaborator OTHER

  • Herlev Hospital

    collaborator OTHER

  • Hillerod Hospital, Denmark

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-12
Primary Completion
2020-09-03
Completion
2020-09-03
FDA Device
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04125160 on ClinicalTrials.gov